Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...

Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

Wall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known consensus ...

We recently compiled a list of the 10 Firms Begin Trading Week With Impressive Gains. In this article, we are going to take a ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, ...

SWTX stock opened at $57.43 on Wednesday. The company has a market cap of $4.27 billion, a price-to-earnings ratio of -14.80 and a beta of 0.81. SpringWorks Therapeutics has a twelve month low of ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

$SWTX insiders have traded $SWTX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales. We have seen ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

BofA analyst Alec Stranahan raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $65 from $55 and keeps a Buy rating on the ...

Whales with a lot of money to spend have taken a noticeably bullish stance on SpringWorks Therapeutics. If we consider the ...